Biotech Companies FAQ

On July 14, 2025, Eli Lilly and Company announced that it had agreed to acquire Verve Therapeutics for approximately $1.3 billion in an all-cash transaction. The deal valued Verve at $10.50 per share plus a $3.00 contingent value right (CVR), representing a 113% premium over Verve's closing price the previous trading day. For a company whose stock had been battered by a clinical setback and whose market capitalization had dwindled to a fraction of its post-IPO peak, the acquisition was a lifeline. For Eli Lilly, it was something far more strategic: a declaration that one of the world's largest pharmaceutical companies believed the future of cardiovascular medicine would be written not in daily pills but in single-dose genetic cures.

In 2013, the race to commercialize CRISPR gene editing was just beginning. Feng Zhang at the Broad Institute had published a landmark paper demonstrating that CRISPR-Cas9 could edit human cells, and the patent filings were already in motion. That same year, Editas Medicine was founded with an extraordinary roster of scientific talent and what appeared to be an insurmountable intellectual property advantage. The company's founding scientific advisors included five pioneers of CRISPR technology: Feng Zhang, George Church, J. Keith Joung, David Liu, and Jennifer Doudna — though Doudna would leave before the company's public debut amid the intensifying patent dispute between the Broad Institute and UC Berkeley.

Verve Therapeutics was founded in 2018 by Sekar Kathiresan, a cardiologist-geneticist who had spent years at the Broad Institute and Massachusetts General Hospital studying the genetics of heart disease. Kathiresan's central insight came from a simple but profound observation in human genetics: people born with naturally occurring loss-of-function mutations in certain genes — particularly PCSK9 and ANGPTL3 — had dramatically lower LDL cholesterol levels and correspondingly lower rates of heart attack and cardiovascular death, with no apparent health consequences from carrying these mutations [6].

Heart disease kills approximately 17.9 million people globally each year, accounting for roughly 32% of all deaths worldwide, according to the World Health Organization [1]. In the United States alone, cardiovascular disease claims about 695,000 lives annually — more than all forms of cancer combined [2]. The economic burden is equally staggering. The American Heart Association estimates that direct and indirect costs of cardiovascular disease in the U.S. exceed $400 billion per year, a figure projected to surpass $1 trillion by 2035 [3].

The gene editing sector reached an inflection point in late 2023 when the FDA and EMA approved Casgevy, the world's first CRISPR-based therapy. That approval transformed gene editing from a laboratory curiosity into a commercial reality — and fundamentally changed the investment thesis for the entire sector. In 2026, the landscape has evolved further, with expanding clinical pipelines, new therapeutic modalities, and growing commercial infrastructure. Here are six companies that investors should be watching closely.

The gene editing market in 2024 encompassed three broad categories: therapeutic applications, research tools and reagents, and agricultural biotechnology. The therapeutic segment, driven by clinical-stage programs and the first approved therapies, accounted for the largest share of market value when measured by projected revenue potential. The research tools segment, while smaller in absolute revenue, generated the most consistent and predictable income through reagent sales, licensing fees, and service contracts.

CRISPR Therapeutics AG (NASDAQ: CRSP) is a gene editing biopharmaceutical company focused on developing transformative therapies for serious diseases. The company was co-founded in 2013 by Emmanuelle Charpentier, who shared the 2020 Nobel Prize in Chemistry with Jennifer Doudna for their pioneering work on the CRISPR-Cas9 gene editing system. Charpentier's foundational research at the University of Vienna and Umea University established the molecular mechanism that made programmable genome editing possible.

Beam Therapeutics is built on base editing, a technology developed by David Liu at the Broad Institute and Harvard University. Base editors use a modified Cas9 protein (which nicks one strand of DNA rather than cutting both) fused to a deaminase enzyme that chemically converts one DNA base to another — for example, changing a cytosine (C) to a thymine (T), or an adenine (A) to a guanine (G). This allows precise correction of point mutations without creating double-strand breaks.

The Lilly-Verve acquisition had significant ripple effects for Beam Therapeutics, the Cambridge-based company that had developed the base editing technology underlying Verve's programs. Beam had been founded in 2017 by David Liu, Feng Zhang, and J. Keith Joung, and had positioned itself as the platform company for base editing — licensing its technology to partners while also developing its own pipeline of base editing therapies, primarily in hematology and oncology.

Casgevy (exagamglogene autotemcel) is the therapy that put CRISPR Therapeutics on the map. Developed in partnership with Vertex Pharmaceuticals, it received approval from the UK's MHRA in November 2023, followed by the European Medicines Agency and the U.S. FDA in December 2023. These approvals covered two indications: sickle cell disease (SCD) in patients with recurrent vaso-occlusive crises and transfusion-dependent beta-thalassemia (TDT).

Editas made a bold bet with its lead program: EDIT-101, a therapy for Leber congenital amaurosis type 10 (LCA10), a rare inherited form of childhood blindness caused by mutations in the CEP290 gene. The program was historically significant — it would become the first attempt to use CRISPR gene editing inside a living human body (in vivo), delivered directly to the retina via subretinal injection using an adeno-associated virus (AAV) vector.

In December 2023, the FDA approved Casgevy, the world's first CRISPR-based therapy. That regulatory milestone did more than validate a single drug — it reset the financial projections for an entire industry. Within twelve months of the Casgevy approval, market research firms were revising their gene editing forecasts upward by 20-30%, and venture capital that had been sitting on the sidelines began flowing back into the sector.

VERVE-102 represented a significant evolution of Verve's technology. While it targeted the same gene (PCSK9) and used the same base editing approach, it incorporated a next-generation lipid nanoparticle delivery system and an optimized guide RNA. The new LNP formulation was designed to improve liver targeting, reduce off-target editing, and lower the inflammatory response that had been observed with earlier LNP formulations.

Editas Medicine was incorporated in November 2013 with $43 million in Series A funding from Flagship Pioneering, Polaris Partners, and Third Rock Ventures — three of the most respected life sciences venture firms in the world. The company's founding thesis was straightforward: license the Broad Institute's CRISPR-Cas9 intellectual property and build a pipeline of gene editing therapies across multiple disease areas.

CRISPR Therapeutics' platform is built on the CRISPR-Cas9 system, which uses a guide RNA to direct the Cas9 enzyme to a specific genomic location where it makes a double-strand break. The cell's natural DNA repair mechanisms then introduce the desired change. The advantages are well-established: CRISPR-Cas9 is programmable, efficient, and has the longest clinical track record of any gene editing technology.

Prime Medicine is commercializing prime editing, arguably the most significant advance in genome editing since CRISPR-Cas9 itself. Invented by David Liu and Andrew Anzalone at the Broad Institute (published in Nature in October 2019), prime editing uses a reverse transcriptase fused to a Cas9 nickase, guided by a prime editing guide RNA (pegRNA) that contains both the target sequence and the desired edit.

Gene editing is transitioning from a research-stage sector to a revenue-generating industry. Casgevy is treating patients. Intellia is in Phase 3. Life Biosciences is testing age reversal in humans. The investment landscape has matured accordingly — from speculative biotech bets to a structured ecosystem of ETFs, thematic indexes, venture funds, and publicly traded companies spanning four continents.

CRISPR Therapeutics (CRSP) holds the distinction of co-developing the first FDA-approved CRISPR therapy. Casgevy, its groundbreaking treatment for sickle cell disease and transfusion-dependent beta-thalassemia developed in partnership with Vertex Pharmaceuticals, reached the market in late 2023. By 2026, the company is focused on scaling commercial delivery of Casgevy while expanding its pipeline.

Intellia's core platform is in vivo CRISPR-Cas9 gene editing — delivering lipid nanoparticles loaded with CRISPR components directly into the bloodstream to edit genes inside the body. This is a fundamentally different model from the ex vivo approach used by Casgevy, which requires extracting a patient's cells, editing them in a laboratory, and reinfusing them after myeloablative conditioning.

The gene editing sector is no longer a monolith. In 2023, the FDA's approval of Casgevy proved that CRISPR-Cas9 could deliver approved therapies. But the next wave of gene editing companies is not building on the same technology — they are building on fundamentally different molecular platforms, each with distinct scientific advantages, clinical risk profiles, and commercial trajectories.

Why it matters: Caribou, co-founded by CRISPR pioneer Jennifer Doudna, is focused on allogeneic (off-the-shelf) cell therapies using its proprietary chRDNA (CRISPR hybrid RNA-DNA) technology. Unlike autologous therapies that require manufacturing from each patient's cells, allogeneic therapies are manufactured in advance, potentially reducing cost and treatment timelines.

Beam Therapeutics (BEAM) is built on base editing technology developed by David Liu at the Broad Institute. Unlike traditional CRISPR, which cuts both strands of DNA, base editors chemically convert one DNA letter to another without making double-strand breaks. This precision approach reduces the risk of unwanted insertions, deletions, and chromosomal rearrangements.

CRISPR Therapeutics is in the early stages of generating product revenue through its share of Casgevy profits. Vertex Pharmaceuticals leads commercialization, with CRISPR Therapeutics receiving profit-sharing payments under their collaboration agreement. Revenue has been growing as patient starts increase, but the ramp has been gradual given treatment complexity.

Gene editing has a bottleneck problem. While CRISPR-Cas9 can theoretically target any DNA sequence, the practical reality is more complicated. Not every guide RNA works equally well. Off-target effects vary unpredictably. Delivery efficiency differs across tissues. And the biological consequences of a given edit are not always obvious from the DNA sequence alone.

Editas Medicine was founded, in large part, on the strength of the Broad Institute's CRISPR-Cas9 patent portfolio. Feng Zhang's group at the Broad filed patent applications and received key U.S. patents covering the use of CRISPR-Cas9 in eukaryotic cells, including human cells. Editas held an exclusive license to these patents for therapeutic applications.

Why it matters: CRISPR Therapeutics holds the distinction of co-developing the first approved CRISPR therapy. Casgevy (exagamglocel autotemcel), developed in partnership with Vertex Pharmaceuticals, treats sickle cell disease and transfusion-dependent beta-thalassemia by editing patients' own hematopoietic stem cells to produce fetal hemoglobin.

Verve Therapeutics (VERV) is taking a bold approach by applying gene editing to the most common cause of death worldwide: cardiovascular disease. The company's lead program, VERVE-101, uses base editing delivered via lipid nanoparticles to inactivate the PCSK9 gene in the liver, permanently lowering LDL cholesterol with a single infusion.

The financial trajectory of Editas Medicine tells a stark story. The company's stock reached its all-time high above $70 per share in early 2021, during the broader biotech and CRISPR enthusiasm that accompanied the COVID-19 mRNA vaccine success (which validated genetic medicine broadly) and the excitement around the BRILLIANCE trial.

Insilico Medicine, founded in 2014 by Alex Zhavoronkov, is one of the most prominent companies at the intersection of AI and drug discovery. The company uses a suite of AI platforms, including its generative chemistry engine Chemistry42 and its target discovery platform PandaOmics, to identify drug targets and design molecules.

Prime Medicine (PRME) is commercializing prime editing, another invention from David Liu's lab. Prime editing has been described as a "search-and-replace" tool for the genome. It can make all 12 types of point mutations, as well as small insertions and deletions, without requiring double-strand breaks or donor DNA templates.

Why it matters: Intellia is the leader in in vivo CRISPR gene editing — administering gene editing therapy directly inside the body via lipid nanoparticle (LNP) delivery, rather than extracting, editing, and reinfusing cells. This approach could fundamentally change the economics and accessibility of gene therapy.

Intellia Therapeutics (NTLA) has positioned itself as the leader in in vivo CRISPR gene editing, meaning it delivers gene editing tools directly into the body rather than editing cells outside the body and reinfusing them. This approach could dramatically expand which diseases CRISPR can treat.

Why it matters: Beam is built on base editing technology licensed from David Liu's laboratory at the Broad Institute. Base editing makes precise single-letter DNA changes without double-strand breaks, potentially offering a safer and more predictable editing profile than standard CRISPR.

Editas Medicine (EDIT) was one of the first CRISPR companies founded, with intellectual property licensed from the Broad Institute based on Feng Zhang's work. The company has had a turbulent journey, including leadership changes and pipeline shifts, but remains a significant player.

Why it matters: Verve is focused exclusively on cardiovascular disease, using base editing to make single-dose genetic treatments for conditions driven by well-characterized genes. The company's approach targets the liver to permanently reduce levels of disease-causing proteins.

Why it matters: Editas was one of the first gene editing companies, founded in 2013 with technology from Feng Zhang's laboratory at the Broad Institute. The company has undergone significant strategic shifts in recent years, refocusing its pipeline after mixed clinical results.

Recursion Pharmaceuticals takes a different approach, treating biology as an information science. The company uses automated high-throughput microscopy combined with machine learning to generate massive datasets of cellular phenotypes, creating what it calls a "map of biology."

Caribou Biosciences (CRBU), co-founded by Jennifer Doudna, has developed a proprietary approach using chemically modified guide RNAs called chRDNAs (CRISPR hybrid RNA-DNA guides). These hybrid guides improve the precision of genome editing by reducing off-target effects.

Perhaps the most futuristic application of AI in gene editing is the design of entirely novel gene editing proteins. Just as large language models can generate coherent text, protein language models can generate novel protein sequences with desired functions.

Disclaimer: This section is for informational and educational purposes only. It does not constitute investment advice. Gene editing stocks are volatile and carry significant risk. Consult a qualified financial advisor before making any investment decisions.

The first and most mature application of AI in gene editing is guide RNA design optimization. Several machine learning models have been developed to predict how effectively a given guide RNA will direct Cas9 (or other Cas proteins) to its target sequence.

Recognizing the limitations of its in vivo-first strategy, Editas also developed an ex vivo program: EDIT-301, later branded as reni-cel (renizgamglogene autotemcel), for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia.

Lilly's acquisition of Verve did not happen in a vacuum. It was part of a broader pattern of major pharmaceutical companies moving aggressively to secure gene editing capabilities — a trend that accelerated dramatically in 2024 and 2025.

CRISPR Therapeutics has been deliberate about building a pipeline that extends well beyond hemoglobinopathies. The company's programs fall into three strategic areas: immuno-oncology, in vivo gene editing, and regenerative medicine.

In 2020, DeepMind's AlphaFold2 solved one of biology's grand challenges: predicting protein three-dimensional structure from amino acid sequence alone. The implications for gene editing have been profound.

One of the most visible symptoms of Editas's struggles was persistent leadership turnover. In biotech, CEO transitions are not uncommon, but the frequency and circumstances at Editas were unusual.

Gene editing does not exist in isolation. It intersects with the broader cell therapy and gene therapy markets in ways that significantly expand the addressable opportunity.

CRISPR Therapeutics operates in an increasingly competitive gene editing landscape. Understanding where it fits relative to peers is essential for evaluating the company.

The gene editing market has a complex competitive landscape that spans pharmaceutical companies, technology platform companies, tool providers, and agricultural firms.

Last updated: March 2026. This article is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.

The Editas story is not one of a single catastrophic failure. It is the accumulation of strategic choices that, in aggregate, left the company behind its competitors.

Sources: Bloomberg consensus, FactSet, and individual analyst reports as of early March 2026. Targets represent sell-side estimates and are inherently uncertain.

The gene editing market is not monolithic. Its growth is driven by three distinct segments, each with different dynamics, customers, and growth drivers.

Regulatory risk: Each new gene editing modality faces novel regulatory pathways. The FDA has no precedent for approving age-reversal therapies.

Understanding the molecular differences between these three technologies is essential for evaluating each company's long-term potential.

The structure of Lilly's acquisition reflected both confidence in the technology and acknowledgment of the remaining clinical risk.

The most transformative gene editing and longevity companies are still private. Here's where institutional capital is flowing:

The gene editing market is often used as a synonym for the CRISPR market, but the technology landscape is far more nuanced.

All three stocks have experienced the broader biotech downturn that began in late 2021 and has only partially reversed.

Several indexes track the genomics and gene editing sector, providing benchmarks and underlying frameworks for ETFs:

The convergence of AI and gene editing is still in its early stages. Over the coming years, we can expect:

ETFs offer the simplest exposure with built-in diversification. Here are the six most relevant funds:

The CRISPR industry has matured significantly. Several trends define the current landscape:

The flow of capital into gene editing tells a compelling story about market confidence.

Gene editing is not a US-only story. Here are the publicly traded companies by region:

The gene editing market is concentrated in North America but increasingly global.

Before choosing investment vehicles, understand the scale:

It did not go smoothly at first.

Intellia: